
NASDAQHealthcareBiotechnology
最新数据
US$121.4
−US$2.62 · -2.11%
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
前收盘价
US$121.4
−US$2.62 · -2.11%
盘中时间采用ET。市场数据可能有所延迟。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日内区间
当前US$121.4
52周区间
当前US$121.4
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
2
估值过高
情绪
59
多空交织
风险
46
风险偏高
动量
80
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
日内区间
当前US$121.4
52周区间
当前US$121.4
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4601.6万 USD | 4.34亿 USD | 6000万 USD | 2658.1万 USD | 2735.7万 USD |
| 销货成本 | 122.5万 USD | — | — | — | — |
| 毛利 | 4479.1万 USD | 4.34亿 USD | 6000万 USD | 2658.1万 USD | 2735.7万 USD |
| 研究与开发 | 1.59亿 USD | 1.38亿 USD | 1.2亿 USD | 1.26亿 USD | 1.26亿 USD |
| 销售、一般及管理费用 | 4485.3万 USD | 4346.2万 USD | 3349.1万 USD | 3173.9万 USD | 2719.6万 USD |
| 营业费用 | 2.03亿 USD | 1.82亿 USD | 1.54亿 USD | 1.58亿 USD | 1.53亿 USD |
| 利息收入 | 2878.9万 USD | 2631.5万 USD | 1489.8万 USD | 406万 USD | 44.3万 USD |
| 折旧和摊销 | 128万 USD | 296.3万 USD | 331.2万 USD | 336.9万 USD | 277.5万 USD |
| 营业利润 | −1.58亿 USD | 2.53亿 USD | −9365.2万 USD | −1.31亿 USD | −1.26亿 USD |
| 净利润 | −1.3亿 USD | 2.75亿 USD | −7895.5万 USD | −1.27亿 USD | −1.26亿 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$175.33
上涨空间 44.42%报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR4.73亿0.48%987亿 USD0.06%US$131.25-2.53%
Vanguard Morningstar Total Stock Market ETFVTI2.34亿0.01%6893亿 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB2.1亿0.12%787亿 USD0.03%US$270.68-2.56%
iShares Russell 2000 ETFIWM2亿0.27%715.37亿 USD0.19%US$256.61-2.88%
State Street SPDR S&P Biotech ETFXBI1.29亿1.34%96.36亿 USD0.35%US$140.18-2.73%
Vanguard Morningstar Small-Cap Growth ETFVBK1.18亿0.27%225亿 USD0.05%US$298.35-3.85%
Vanguard Extended Market ETFVXF1.06亿0.11%302亿 USD0.05%US$211.44-3.21%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM7350.26万0.48%152.94亿 USD0.03%US$50.99-2.58%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。